Cargando…

Radiosynthesis and in vivo evaluation of (11)C-labeled BMS-193885 and its desmethyl analog as PET tracers for neuropeptide Y1 receptors

BACKGROUND: Neuropeptide Y (NPY) has been implicated in a wide variety of physiological processes, including feeding, learning, memory, emotion, cardiovascular homeostasis, hormone secretion, and circadian rhythms. NPY Yl receptor (NPY Y1-R) is the most widely studied NPY receptor, and is involved i...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawamura, Kazunori, Mori, Wakana, Fujinaga, Masayuki, Yamasaki, Tomoteru, Zhang, Yiding, Wakizaka, Hidekatsu, Hatori, Akiko, Xie, Lin, Kumata, Katsushi, Ohkubo, Takayuki, Kurihara, Yusuke, Ogawa, Masanao, Nengaki, Nobuki, Zhang, Ming-Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379498/
https://www.ncbi.nlm.nih.gov/pubmed/31659508
http://dx.doi.org/10.1186/s41181-019-0056-5
Descripción
Sumario:BACKGROUND: Neuropeptide Y (NPY) has been implicated in a wide variety of physiological processes, including feeding, learning, memory, emotion, cardiovascular homeostasis, hormone secretion, and circadian rhythms. NPY Yl receptor (NPY Y1-R) is the most widely studied NPY receptor, and is involved in many of these processes. BMS-193885 (1) was previously developed as a potent and selective NPY Y1-R antagonist, which has good systemic bioavailability and brain penetration. To evaluate the characteristics of 1 in vivo, we developed (11)C-labeled BMS-193885 ([(11)C]1) and its desmethyl analog ([(11)C]2) for potential use as two new positron emission tomography (PET) tracers. RESULTS: [(11)C]1 was synthesized from [(11)C]methyl iodide using 2. [(11)C]2 was synthesized from [(11)C]phosgene using its aniline and amine derivatives. The mean ± S.D. decay-corrected radiochemical yields of [(11)C]1 and [(11)C]2 from (11)CO(2) at the end of radionuclide production were 23 ± 3.2% (n = 6) and 24 ± 1.5% (n = 4), respectively. In biodistribution on mice, radioactivity levels for both tracers were relatively high in the kidney, small intestine, and liver at 60 min post-injection. The radioactivity levels in the kidney, lung, and spleen of mice at 30 min post-injection with [(11)C]1 were significantly reduced by pretreatment with 1 (10 mg/kg), and levels of [(11)C]1 in the brain of mice were significantly increased by pretreatment with the P-glycoprotein and breast cancer resistance protein inhibitor elacridar (10 mg/kg). In metabolite analysis using mouse plasma, [(11)C]1 and [(11)C]2 were rapidly metabolized within 30 min post-injection, and [(11)C]1 was mainly metabolized into unlabeled 2 and radiolabeled components. CONCLUSION: [(11)C]1 and [(11)C]2 were successfully synthesized with sufficient amount of radioactivity and high quality for use in vivo. Our study of [(11)C]1 and its desmethyl analog [(11)C]2 was useful in that it helped to elucidate the in vivo characteristics of 1. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s41181-019-0056-5) contains supplementary material, which is available to authorized users.